Beijing Luzhu Biopharmaceutical

Company snapshot

Beijing Zhifei Lvzhu is a biotech organization headquartered in CN. Primary therapeutic focus areas include Locally Advanced Breast Cancer (LABC), Mantle Cell Lymphoma, Systemic Lupus Erythematosus, Meningitis, Pneumococcal Vaccines. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (3), phase 2 (2), phase 3 (2).

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Beijing Luzhu Biopharmaceutical. Not investment advice.

• What is Beijing Luzhu Biopharmaceutical?

  Beijing Zhifei Lvzhu is a biotech organization headquartered in CN. Primary therapeutic focus areas include Locally Advanced Breast Cancer (LABC), Mantle Cell Lymphoma, Systemic Lupus Erythematosus, Meningitis, Pneumococcal Vaccines. NovaPharmaNews links 7 clinical program(s), 0

• Is Beijing Luzhu Biopharmaceutical publicly traded?

  Beijing Luzhu Biopharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Beijing Luzhu Biopharmaceutical develop or market?

  We link 5 drug profile(s) where Beijing Luzhu Biopharmaceutical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/beijing-zhifei-lvzhu-biopharmaceutical-co-ltd#company-drugs.

• What are the latest developments for Beijing Luzhu Biopharmaceutical?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Beijing Luzhu Biopharmaceutical focus on?

  Beijing Luzhu Biopharmaceutical focuses on Locally Advanced Breast Cancer (LABC), Mantle Cell Lymphoma, Systemic Lupus Erythematosus based on our analysis of their pipeline programs and drug development activities.